EFB Dengue Literature Review

BLIMP-1

10 min read

BLIMP-1

Overview

BLIMP-1 (B Lymphocyte-Induced Maturation Protein 1; encoded by PRDM1) is an IRF4-induced transcriptional repressor that silences B cell programmes and induces plasma cell differentiation. BLIMP-1 expression is a hallmark of committed PC fate. In DN2 and aNAV B cells, BLIMP-1 is upregulated at both mRNA and protein level, and the PRDM1 locus shows open chromatin by ATAC-seq — indicating these populations are epigenetically poised for PC differentiation.

Key Points from Literature

  • Elevated in DN2 and aNAV: BLIMP-1 protein (flow cytometry MFI) is higher in aNAV and DN2 cells than in rNAV, SWM, and DN1 (p<0.001). Only PC have higher expression (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, flow cytometry n=4).

  • PRDM1 transcription: PRDM1 mRNA is upregulated in DN2 relative to rNAV cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq).

  • Epigenetic priming: ATAC-seq demonstrates opening of the PRDM1 locus in aNAV and DN2 cells — chromatin accessibility consistent with poised transcription (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • BACH2 silencing enables BLIMP-1: BACH2, the main negative regulator of PRDM1 transcription, is absent in DN2 and aNAV cells. Removal of BACH2 repression allows BLIMP-1 upregulation (see Jenks2018 - DN2 B Cells and EF Pathway in SLE; see also BACH2).

  • BLIMP-1/PRDM1 pathway operative in COVID-19 EF ASCs: The massive germline-dominant ASC expansion in severe COVID-19 — with >50% unmutated VH, ongoing CSR, and EF cellular hallmarks (aN/DN2/DN3 expansion) — is consistent with BLIMP-1-driven terminal differentiation of naive-derived precursors via the EF pathway, as defined by the PRDM1 locus opening in DN2/aNAV cells (see Woodruff2020 - EF B Cell Responses in COVID-19, n=17 COVID-19 prospective cohort; repertoire data from n=1 single-cell + n=2 bulk V(D)J).

  • PRDM1/Blimp-1 is part of the DN2 ASC-poised TF network: In the comprehensive SLE DN2 characterisation, overexpression of PRDM1/Blimp-1 alongside IRF4 and Zbtb32 positions DN2 cells for rapid ASC differentiation — a programme confirmed across mouse and human ABC (see Sanz2025 - Human Atypical B Cells Overview, review).

  • PRDM1 promoter shows progressive demethylation and increased accessibility across B cell differentiation: RRBS and ATAC-seq data confirmed increasing PRDM1 promoter accessibility and decreasing DNA methylation from resting naive through to DN2 and switched memory, most pronounced in DN2. This epigenetic priming was accompanied by transcriptional upregulation of PRDM1 and SLAMF7 (see Scharer2019 - Epigenetic Programming in SLE B Cells, RRBS + ATAC-seq + RNA-seq, n=9 SLE + n=12 HC).

  • PRDM1 (BLIMP-1) NOT upregulated in alternative lineage atBC clusters: scRNA-seq showed that PRDM1 was not upregulated in any atBC cluster or MBC1, with PCs detached from the alternative lineage pseudotime manifold. Combined with absent XBP1 and IRF4, this argues that the BLIMP-1-driven PC programme is not activated in atBCs outside of pathological contexts (SLE). The contrast with elevated BLIMP-1 protein in SLE DN2 cells (Jenks2018) suggests that BLIMP-1 upregulation in DN2 is disease-specific rather than intrinsic to the alternative lineage (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium).

  • ★ Prdm1 chromatin accessibility increases with cumulative antigenic stimulation — the proposed epigenetic basis of memory fate. Repeated or prolonged stimulation progressively opens PC-associated gene loci including Prdm1, thereby increasing baseline BLIMP1 expression and biasing memory B cells toward plasma-cell differentiation over germinal-center reentry. The model proposes that MBC fate on reactivation is programmed not by a binary GC vs non-GC origin but by the cumulative history of stimulation recorded epigenetically, acting in part through BACH2 and BLIMP1 (see Glaros2025 - Multilayered Identity of B Cell Memory, review, no original data; the authors flag it as untested). This adds a mechanism to the wiki’s existing observation that the PRDM1 locus is already open by ATAC-seq in DN2 cells (Jenks2018 - DN2 B Cells and EF Pathway in SLE) — on this model, open PRDM1 is a record of accumulated stimulation, not merely a lineage marker.

  • In the germinal center, Prdm1 is actively repressed by BACH2 under weak T cell help, which is how low-affinity GC B cells are diverted into the quiescent memory fate rather than the plasma-cell fate (see Glaros2025 - Multilayered Identity of B Cell Memory, review, mouse). See BACH2, Germinal Center.

  • Atypical B cells express PC-associated genes — one of the lines the review cites for ABCs being transcriptionally primed for PC differentiation (citing Song 2022, mouse). ⚠ Note this stands in unresolved tension with Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, which found no upregulation of PRDM1, XBP1, or IRF4 in human atBC clusters at steady state — see DN2 B Cell Contradictions for the reconciliation attempt.

  • ⚠ RESOLVED [2026-09-04] — Cancro’s “T-bet represses Blimp-1” is contradicted in B cells by primary data. ABCs are described as differentiating rapidly to ASC/plasmablasts on TLR7/9 + IL-21 stimulation (citing Wang 2018 and Jenks2018 - DN2 B Cells and EF Pathway in SLE), and Cancro states there is evidence that T-bet represses Blimp-1, implying that plasma cell formation from ABCs likely involves loss of T-bet expression (see Cancro2020 - Age-Associated B Cells, review — no original data, no numbered reference attached to the sentence). Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation tested it directly in mouse B cells and found no repressive relationship — see the two bullets below. The probable provenance is the T cell literature (Oestreich 2012, Xin 2016), which is what Stone cites when noting that Blimp-1 “can be modulated in a T-bet-dependent fashion in T cells.” The first clause of Cancro’s sentence — “few if any plasma cells express T-bet” — survives only for the terminal bone-marrow compartment; see T-bet for the splenic-vs-BM reporter gradient.

  • BLIMP-1 with retained Pax5 is the review’s definition of the pre-plasmablast. Core markers resolve “an additional population of proliferative IgD⁻CD38⁺/⁺⁺CD24⁻ cells expressing low levels of CD27”: these upregulate BLIMP-1 while maintaining Pax5, and are therefore read as PB precursors. The review also notes that although IgD⁺ ASC have been described, only a small fraction express BLIMP-1 and they are rarely found in the periphery (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data). See Plasmablast, XBP1.

  • ★ IFN-γ opens the PRDM1 programme; T-bet does not — the two signals dissociate. Stone’s cleanest internal control uses one assay and one motif set with two perturbations. Chromatin accessibility in the 100 bp around Blimp-1 binding motifs (n=871 motif-containing DARs) is strongly opened by Th1 priming (day-2 B6 Be1 vs Be2, p=3.8 × 10⁻⁹⁰) but unchanged when T-bet is deleted (B6 Be1 vs Tbx21^−/−^ Be1, ns) — while T-bet’s own motifs (n=963) are strongly differential in the same panel. Prdm1 mRNA is likewise equivalent in day-2 B6 vs Tbx21^−/−^ Be1 cells; by day 4 it is lower without T-bet, i.e. T-bet indirectly supports Blimp-1 and never represses it. The receptor arm confirms the split: Ifngr1^−/−^ Be1 cells show significantly reduced Prdm1 at day 2, keep Prdm1/Irf4/Pou2af1/Xbp1 low through day 4, form almost no ASC (15.3% → 0.6%) and secrete no antibody. Knocking out the receptor kills the PC programme; knocking out the transcription factor does not (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, Be1/Be2 co-culture + ATAC-seq + qPCR, 3 samples/group).

  • BLIMP-1 is required for ASC formation in this system — the positive control. Cd19^cre/+^Prdm1^fl/fl^ Be1 cells fall from 7.9% to 1.7% CD138⁺CD93⁺ ASC with antibody secretion reduced to near zero (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro). Stone’s own framing: T-bet, “unlike Blimp1 or IRF4, is not a master regulator of ASC development.”

  • ★ IFN-γ priming remodels the PRDM1 locus itself, and 3 of the 4 sites are shared with patient DN2 cells. ATAC-seq at day 3 identified 4 differentially accessible regions at the PRDM1 (BLIMP1) locus in the IFN-γ+IL-2 condition, and chromatin around BLIMP1 binding motifs genome-wide was highly enriched in that condition — all before IL-21 was added. None of the 4 PRDM1 DARs contained a T-bet motif, but each aligned with a published T-bet ChIP-seq peak (ENCODE GM12878), suggesting T-bet acts within complexes rather than by direct motif binding there. 3 of the 4 were also present in T-bet^hi^ DN2 cells purified from SLE patients, tying the in vitro construct to the patient population (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction, ATAC-seq n=2/group). ⚠ Read this together with the Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation bullets above and keep the two claims distinct: Zumaquero shows IFN-γ opens PRDM1 and BLIMP1-motif chromatin in human cells; Stone shows T-bet deletion leaves Blimp-1-motif accessibility unchanged in mouse. Same lab, compatible results, different perturbations — the opener is the cytokine, not the transcription factor.

  • Murine T-bet⁺CD11c⁺ B cells express Prdm1 highly — the opposite sign to the human atypical B cell result, and worth reading carefully. Sorted day-12 RNA-seq put Prdm1 among the highly expressed genes alongside Xbp1, Zeb2, Bhlhe41, Zbtb32, Tnfrsf17 (BCMA) and Sdc1. But surface CD138 was not increased and autoantibody secretion still required R848 stimulation, so a high Prdm1 transcript here indicates capability rather than completed ASC differentiation (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse, LCMV-Armstrong, n=3–5 mice/group). Contrast Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, which found no upregulation of PRDM1/XBP1/IRF4 in human atBC at rest — see Contradictions below.

Contradictions & Debates

  • The Sutton2021/Jenks2018 contradiction remains open — but a mechanism is now proposed. Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection finds no upregulation of PC-programme genes (PRDM1/BLIMP-1, XBP1, IRF4) in atBC clusters at rest (n=4, scRNA-seq); Jenks2018 - DN2 B Cells and EF Pathway in SLE finds DN2 cells are efficient plasmablast precursors on stimulation, with BLIMP-1 protein elevated and the PRDM1 locus open by ATAC-seq. Cancro’s unreferenced T-bet-represses-Blimp-1 assertion is not the basis for reconciling them — it is now contradicted outright (see the Key Points flag above).
    • The proposed reconciliation is that T-bet is permissive, not instructive. On Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation’s model, T-bet does not induce the PC programme at all; it represses the IFN-γ-driven inflammatory brake (NF-κB, TLR, STAT/IRF) that would otherwise hold an activated B cell in an effector state. If so, both observations hold at once: Sutton sees no PC genes in resting atypical cells because T-bet does not induce them, and Jenks sees efficient plasmablast output on stimulation because the brake has been lifted.
    • ⚠ This is a mechanism proposed, not a contradiction closed. Stone is mouse Be1/Be2 co-culture plus influenza and does not examine human atypical B cells. Both Sutton and Jenks are human. The reconciliation is untested at the level the disagreement was actually observed, and the direct human test — showing that sustained NF-κB/TLR signalling suppresses ASC output from sorted human DN2 cells — is supplied by no source in the wiki. Tracked as a Watch Item.

IRF4, BACH2, DN2 B Cell, Activated Naive B Cell, Plasmablast, Extrafollicular Response, BACH2, Memory B Cell, Early Memory B Cell, Original Antigenic Sin

Sources

Graph View

Backlinks